Chemoinformaics analysis of TETRADEC-13-ENYL ACETATE
| Molecular Weight | 254.414 | nRot | 13 |
| Heavy Atom Molecular Weight | 224.174 | nRig | 19 |
| Exact Molecular Weight | 254.225 | nRing | 0 |
| Solubility: LogS | -1.506 | nHRing | 0 |
| Solubility: LogP | 1.384 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 48 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 18 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 30 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 16 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 48.3278 |
| nHD | 0 | BPOL | 32.7002 |
| QED | 0.817 |
| Synth | 3.659 |
| Natural Product Likeliness | 1.26 |
| NR-PPAR-gamma | 0.005 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.058 |
| Pgp-sub | 0.011 |
| HIA | 0.006 |
| CACO-2 | -4.748 |
| MDCK | 0.00000755 |
| BBB | 0.622 |
| PPB | 0.517355 |
| VDSS | 2.058 |
| FU | 0.506259 |
| CYP1A2-inh | 0.735 |
| CYP1A2-sub | 0.741 |
| CYP2c19-inh | 0.096 |
| CYP2c19-sub | 0.834 |
| CYP2c9-inh | 0.044 |
| CYP2c9-sub | 0.314 |
| CYP2d6-inh | 0.967 |
| CYP2d6-sub | 0.913 |
| CYP3a4-inh | 0.079 |
| CYP3a4-sub | 0.671 |
| CL | 15.065 |
| T12 | 0.824 |
| hERG | 0.266 |
| Ames | 0.801 |
| ROA | 0.798 |
| SkinSen | 0.816 |
| Carcinogencity | 0.341 |
| EI | 0.026 |
| Respiratory | 0.968 |
| NR-Aromatase | 0.005 |
| Antiviral | Yes |
| Prediction | 0.746337 |